Pilot Study for Optimization of Immuno-PET Pretargeted With Anti-CEA Bispecific Antibody X Anti-HSG TF2 and the Peptide IMP-288 Radiolabeled With Gallium-68 -Pharmacokinetic and Imaging for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Gallium-68-IMP-288 (Primary) ; TF 2 (Primary)
- Indications Cancer metastases
- Focus Diagnostic use
- Acronyms iTEPsein
- 26 Jul 2018 Status changed from active, no longer recruiting to completed.
- 17 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Apr 2017.
- 17 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2017.